{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T02:48:42Z","timestamp":1790822922583,"version":"4.1.0"},"reference-count":26,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2018,2,1]],"date-time":"2018-02-01T00:00:00Z","timestamp":1517443200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2018,2,1]],"date-time":"2018-02-01T00:00:00Z","timestamp":1517443200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2019,2,14]],"date-time":"2019-02-14T00:00:00Z","timestamp":1550102400000},"content-version":"am","delay-in-days":378,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"funder":[{"DOI":"10.13039\/100003421","name":"Southeastern Brain Tumor Foundation","doi-asserted-by":"publisher","award":["CA182025"],"award-info":[{"award-number":["CA182025"]}],"id":[{"id":"10.13039\/100003421","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Bioorganic &amp; Medicinal Chemistry Letters"],"published-print":{"date-parts":[[2018,2]]},"DOI":"10.1016\/j.bmcl.2018.01.015","type":"journal-article","created":{"date-parts":[[2018,1,12]],"date-time":"2018-01-12T03:30:05Z","timestamp":1515727805000},"page":"694-699","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":29,"title":["Synthesis and evaluation of radiolabeled AGI-5198 analogues as candidate radiotracers for imaging mutant IDH1 expression in tumors"],"prefix":"10.1016","volume":"28","author":[{"given":"Satish K.","family":"Chitneni","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zachary J.","family":"Reitman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rebecca","family":"Spicehandler","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David M.","family":"Gooden","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hai","family":"Yan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael R.","family":"Zalutsky","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.bmcl.2018.01.015_b0005","doi-asserted-by":"crossref","first-page":"765","DOI":"10.1056\/NEJMoa0808710","article-title":"IDH1 and IDH2 mutations in gliomas","volume":"360","author":"Yan","year":"2009","journal-title":"N Engl J Med"},{"key":"10.1016\/j.bmcl.2018.01.015_b0010","doi-asserted-by":"crossref","first-page":"3270","DOI":"10.1073\/pnas.1019393108","article-title":"Profiling the effects of isocitrate dehydrogenase 1 and 2 mutations on the cellular metabolome","volume":"108","author":"Reitman","year":"2011","journal-title":"PNAS"},{"key":"10.1016\/j.bmcl.2018.01.015_b0015","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1093\/neuonc\/nov136","article-title":"Isocitrate dehydrogenase mutations in gliomas","volume":"18","author":"Waitkus","year":"2016","journal-title":"Neuro Oncol"},{"key":"10.1016\/j.bmcl.2018.01.015_b0020","doi-asserted-by":"crossref","first-page":"739","DOI":"10.1038\/nature08617","article-title":"Cancer-associated IDH1 mutations produce 2-hydroxyglutarate","volume":"462","author":"Dang","year":"2009","journal-title":"Nature"},{"key":"10.1016\/j.bmcl.2018.01.015_b0025","doi-asserted-by":"crossref","first-page":"339","DOI":"10.1084\/jem.20092506","article-title":"Cancer-associated metabolite 2-hydroxyglutarate accumulates in acute myelogenous leukemia with isocitrate dehydrogenase 1 and 2 mutations","volume":"207","author":"Gross","year":"2010","journal-title":"J Exp Med"},{"key":"10.1016\/j.bmcl.2018.01.015_b0030","doi-asserted-by":"crossref","first-page":"1149","DOI":"10.2353\/ajpath.2009.080958","article-title":"IDH1 mutations are early events in the development of astrocytomas and oligodendrogliomas","volume":"174","author":"Watanabe","year":"2009","journal-title":"Am J Pathol"},{"key":"10.1016\/j.bmcl.2018.01.015_b0035","doi-asserted-by":"crossref","first-page":"1058","DOI":"10.1056\/NEJMoa0903840","article-title":"Recurring mutations found by sequencing an acute myeloid leukemia genome","volume":"361","author":"Mardis","year":"2009","journal-title":"N Engl J Med"},{"key":"10.1016\/j.bmcl.2018.01.015_b0040","doi-asserted-by":"crossref","first-page":"3091","DOI":"10.1038\/onc.2012.315","article-title":"Mutations in isocitrate dehydrogenase 1 and 2 occur frequently in intrahepatic cholangiocarcinomas and share hypermethylation targets with glioblastomas","volume":"32","author":"Wang","year":"2013","journal-title":"Oncogene"},{"key":"10.1016\/j.bmcl.2018.01.015_b0045","doi-asserted-by":"crossref","first-page":"1256","DOI":"10.1038\/ng.1004","article-title":"Somatic mosaic IDH1 and IDH2 mutations are associated with enchondroma and spindle cell hemangioma in Ollier disease and Maffucci syndrome","volume":"43","author":"Pansuriya","year":"2011","journal-title":"Nat Genet"},{"key":"10.1016\/j.bmcl.2018.01.015_b0050","doi-asserted-by":"crossref","first-page":"305","DOI":"10.1146\/annurev-biochem-061516-044732","article-title":"Isocitrate dehydrogenase mutation and (R)-2-hydroxyglutarate: from basic discovery to therapeutics development","volume":"86","author":"Dang","year":"2017","journal-title":"Annu Rev Biochem"},{"key":"10.1016\/j.bmcl.2018.01.015_b0055","doi-asserted-by":"crossref","first-page":"626","DOI":"10.1126\/science.1236062","article-title":"An inhibitor of mutant IDH1 delays growth and promotes differentiation of glioma cells","volume":"340","author":"Rohle","year":"2013","journal-title":"Science"},{"key":"10.1016\/j.bmcl.2018.01.015_b0060","doi-asserted-by":"crossref","first-page":"850","DOI":"10.1021\/ml300225h","article-title":"Discovery of the first potent inhibitors of mutant IDH1 that lower tumor 2-HG in vivo","volume":"3","author":"Popovici-Muller","year":"2012","journal-title":"ACS Med Chem Lett"},{"key":"10.1016\/j.bmcl.2018.01.015_b0065","doi-asserted-by":"crossref","first-page":"975","DOI":"10.1002\/(SICI)1099-1344(199910)42:10<975::AID-JLCR256>3.0.CO;2-E","article-title":"2-[F-18]fluoropyridines by no-carrier-added nucleophilic aromatic substitution with [F-18]FK-K-222 \u2013 a comparative study","volume":"42","author":"Dolci","year":"1999","journal-title":"J Label Compd Radiopharm"},{"key":"10.1016\/j.bmcl.2018.01.015_b0070","doi-asserted-by":"crossref","first-page":"218","DOI":"10.1016\/j.ejmech.2016.04.066","article-title":"Radiolabeled inhibitors as probes for imaging mutant IDH1 expression in gliomas: synthesis and preliminary evaluation of labeled butyl-phenyl sulfonamide analogs","volume":"119","author":"Chitneni","year":"2016","journal-title":"Eur J Med Chem"},{"key":"10.1016\/j.bmcl.2018.01.015_b0075","doi-asserted-by":"crossref","first-page":"13717","DOI":"10.1074\/jbc.M113.511030","article-title":"Biochemical, cellular, and biophysical characterization of a potent inhibitor of mutant isocitrate dehydrogenase IDH1","volume":"289","author":"Davis","year":"2014","journal-title":"J Biol Chem"},{"key":"10.1016\/j.bmcl.2018.01.015_b0080","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1016\/j.nucmedbio.2010.07.006","article-title":"Radioiodinated O-6-benzylguanine derivatives containing an azido function","volume":"38","author":"Vaidyanathan","year":"2011","journal-title":"Nucl Med Biol"},{"key":"10.1016\/j.bmcl.2018.01.015_b0085","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1039\/a809349k","article-title":"Facile synthesis of substituted diaryliodonium tosylates by treatment of aryltributylstannanes with Koser's reagent","author":"Pike","year":"1999","journal-title":"J Chem Soc Perkin Trans 1"},{"key":"10.1016\/j.bmcl.2018.01.015_b0090","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1039\/C0SC00362J","article-title":"Convergent F-18 radiosynthesis: a new dimension for radiolabelling","volume":"2","author":"Li","year":"2011","journal-title":"Chem Sci"},{"key":"10.1016\/j.bmcl.2018.01.015_b0095","doi-asserted-by":"crossref","first-page":"2959","DOI":"10.1016\/j.bmc.2011.03.032","article-title":"Metabolic stability of 6,7-dialkoxy-4-(2-, 3- and 4-[F-18]fluoroanilino)quinazolines, potential EGFR imaging probes","volume":"19","author":"Vasdev","year":"2011","journal-title":"Bioorg Med Chem"},{"key":"10.1016\/j.bmcl.2018.01.015_b0100","first-page":"2339","article-title":"A heterozygous IDH1R132H\/WT mutation induces genome-wide alterations in DNA methylation","volume":"22","author":"Duncan","year":"2012","journal-title":"Genes Dev"},{"key":"10.1016\/j.bmcl.2018.01.015_b0105","doi-asserted-by":"crossref","first-page":"496","DOI":"10.1158\/0008-5472.CAN-12-2852","article-title":"Disruption of wild-type IDH1 suppresses D-2-hydroxyglutarate production in IDH1-mutated gliomas","volume":"73","author":"Jin","year":"2013","journal-title":"Cancer Res"},{"key":"10.1016\/j.bmcl.2018.01.015_b0110","doi-asserted-by":"crossref","first-page":"762","DOI":"10.1074\/jbc.M114.608497","article-title":"Selective inhibition of mutant isocitrate dehydrogenase 1 (IDH1) via disruption of a metal binding network by an allosteric small molecule","volume":"290","author":"Deng","year":"2015","journal-title":"J Biol Chem"},{"key":"10.1016\/j.bmcl.2018.01.015_b0115","doi-asserted-by":"crossref","first-page":"431","DOI":"10.1016\/j.tips.2009.05.005","article-title":"PET radiotracers: crossing the blood-brain barrier and surviving metabolism","volume":"30","author":"Pike","year":"2009","journal-title":"Trends Pharmacol Sci"},{"key":"10.1016\/j.bmcl.2018.01.015_b0120","article-title":"IDH1 mutations in glioma: considerations for radiotracer development","volume":"2","author":"Chitneni","year":"2016","journal-title":"SM Radiol J"},{"key":"10.1016\/j.bmcl.2018.01.015_b0125","doi-asserted-by":"crossref","first-page":"449","DOI":"10.1016\/j.nucmedbio.2006.03.008","article-title":"Discussion of targeting proteins in vivo: in vitro guidelines","volume":"33","author":"Eckelman","year":"2006","journal-title":"Nuc Med Biol"},{"key":"10.1016\/j.bmcl.2018.01.015_b0130","doi-asserted-by":"crossref","first-page":"478","DOI":"10.1158\/2159-8290.CD-16-1034","article-title":"AG-221, a first-in-class therapy targeting acute myeloid leukemia harboring oncogenic IDH2 mutations","volume":"7","author":"Yen","year":"2017","journal-title":"Cancer Discovery"}],"container-title":["Bioorganic &amp; Medicinal Chemistry Letters"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0960894X18300234?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0960894X18300234?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,18]],"date-time":"2025-10-18T07:21:31Z","timestamp":1760772091000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0960894X18300234"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,2]]},"references-count":26,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2018,2]]}},"alternative-id":["S0960894X18300234"],"URL":"https:\/\/doi.org\/10.1016\/j.bmcl.2018.01.015","relation":{},"ISSN":["0960-894X"],"issn-type":[{"value":"0960-894X","type":"print"}],"subject":[],"published":{"date-parts":[[2018,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Synthesis and evaluation of radiolabeled AGI-5198 analogues as candidate radiotracers for imaging mutant IDH1 expression in tumors","name":"articletitle","label":"Article Title"},{"value":"Bioorganic & Medicinal Chemistry Letters","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.bmcl.2018.01.015","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2018 Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}]}}